Contrary to the conventional recommendation, researchers analyzed SEER data (2004-2015) for stage III rectal mucinous adenocarcinoma (RMC) patients. RMC, distinct in T and N stage at diagnosis, emerged as an independent poor prognostic factor for overall and cancer-specific survival. Notably, adjuvant radiotherapy failed to confer survival benefits, with no significant difference found between chemotherapy alone and chemotherapy plus radiotherapy groups. The study challenges the necessity of adjuvant radiotherapy for stage III RMC, emphasizing its limited efficacy in improving survival outcomes.
Journal Article by Liao H, Tang C (…) Lei X et 6 al. in J Gastrointest Surg
© 2023. The Society for Surgery of the Alimentary Tract.